#1 Clinical Trials Search in Europe

Cimetidine Hydrochloride

This article discusses the use of Cimetidine Hydrochloride in clinical trials for treating advanced or metastatic non-small cell lung cancer (NSCLC). The drug is being studied as part of a combination therapy with other medications to evaluate its safety, effectiveness, and potential benefits for patients with this serious condition.

Table of Contents

What is Cimetidine Hydrochloride?

Cimetidine Hydrochloride is an active substance used in medications. It belongs to a class of drugs known as histamine-2 (H2) blockers. These medications work by reducing the amount of acid produced in the stomach[1].

Medical Uses

While the specific medical uses are not explicitly stated in the provided information, Cimetidine Hydrochloride is typically used to treat various conditions related to excess stomach acid, such as:

  • Gastroesophageal reflux disease (GERD): A condition where stomach acid frequently flows back into the esophagus
  • Peptic ulcers: Sores that develop on the lining of the stomach or small intestine
  • Zollinger-Ellison syndrome: A rare condition that causes tumors in the pancreas or duodenum, leading to increased stomach acid production
  • Heartburn: A burning sensation in the chest caused by stomach acid

It’s important to note that the exact use may vary depending on the specific formulation and prescription[1].

Administration

The information provided does not specify the exact route of administration for this particular formulation of Cimetidine Hydrochloride. However, it’s listed as “UNKNOWN USE” in the data[1]. Typically, Cimetidine is available in various forms, including:

  • Oral tablets
  • Oral liquid
  • Injectable solutions

The specific form and method of administration should be determined by your healthcare provider based on your individual needs and condition.

Dosage

The dosage information for this specific formulation is not provided in the given data. The dosage can vary depending on several factors, including:

  • The condition being treated
  • The severity of the condition
  • The patient’s age and overall health
  • Other medications the patient may be taking

It’s crucial to follow the dosage instructions provided by your healthcare provider or as indicated on the prescription label[1].

Duration of Treatment

The data indicates a maximum treatment period of 75 days for this formulation of Cimetidine Hydrochloride[1]. However, the actual duration of treatment may vary depending on your specific condition and response to the medication. Always follow your healthcare provider’s instructions regarding the length of treatment.

Important Considerations

When taking Cimetidine Hydrochloride, keep the following points in mind:

  • Pediatric use: The data indicates that this is not a pediatric formulation[1]. Always consult with a pediatrician before giving this medication to children.
  • Interactions: Cimetidine can interact with other medications. Inform your healthcare provider about all the medicines you’re taking, including over-the-counter drugs and supplements.
  • Side effects: Like all medications, Cimetidine can cause side effects. Common side effects may include headache, dizziness, and diarrhea. Consult your healthcare provider if you experience any unusual or severe side effects.
  • Regular monitoring: Your healthcare provider may want to monitor your progress regularly to ensure the medication is working effectively and safely.

Remember, this information is general, and your specific treatment plan may differ. Always consult with your healthcare provider for personalized medical advice and follow their instructions carefully[1].

Aspect Details
Study Type Phase II clinical trial
Target Condition Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Treatment Cimetidine Hydrochloride in combination with other drugs
Primary Objectives Evaluate safety, tolerability, and objective response rate (ORR)
Secondary Objectives Assess duration of response, progression-free survival, overall survival, pharmacokinetics, and immunogenicity
Eligibility Adults (18+) with confirmed advanced NSCLC, meeting specific health criteria
Study Design Screening period, treatment period, and survival follow-up period
Treatment Duration Until discontinuation criteria are met

FAQ

  • What is Cimetidine Hydrochloride? Cimetidine Hydrochloride is a medication being studied in clinical trials for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). It is being evaluated as part of a combination therapy with other drugs.
  • What type of cancer is being targeted in these clinical trials? The clinical trials are focusing on advanced or metastatic non-small cell lung cancer (NSCLC). This includes patients with locally advanced (stage IIIB/IIIC) or metastatic (Stage IV) NSCLC that cannot be treated with surgery or radiation therapy alone.
  • What are the main objectives of the clinical trials? The main objectives are to evaluate the safety and tolerability of the combination therapy including Cimetidine Hydrochloride, and to assess the objective response rate (ORR) in patients with advanced or metastatic NSCLC.
  • Who is eligible to participate in these clinical trials? Eligible participants are adults (18 years or older) with confirmed NSCLC that is locally advanced or metastatic. They must meet specific criteria regarding their cancer type, previous treatments, and overall health status. Detailed eligibility criteria are provided by the study coordinators.
  • What are some of the exclusion criteria for these trials? Some exclusion criteria include having mixed small cell lung cancer features, uncontrolled systemic diseases, active autoimmune diseases, hepatitis B or C, HIV, active tuberculosis, and certain cardiovascular conditions. Patients who have recently received other cancer treatments or have participated in other clinical trials may also be excluded.

Ongoing Clinical Trials on Cimetidine Hydrochloride

  • Study of SKB264 and Pembrolizumab for Treating Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Romania Spain

Glossary

  • Non-small cell lung cancer (NSCLC): A type of lung cancer that includes several subtypes, such as adenocarcinoma and squamous cell carcinoma. It is the most common form of lung cancer.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Objective response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall survival (OS): The length of time from the start of treatment that patients are still alive.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • EGFR: Epidermal Growth Factor Receptor, a protein found on cells that plays a role in cell growth. Some NSCLC tumors have mutations in the EGFR gene.
  • ALK: Anaplastic Lymphoma Kinase, a gene that can play a role in lung cancer when it becomes altered.

References

  1. http://clinicaltrials.eu/trial/study-of-skb264-and-pembrolizumab-for-treating-patients-with-advanced-non-small-cell-lung-cancer/